Starting next year, Medicare recipients will see a $2,000 out-of-pocket cap on some prescription drugs as part of several new provisions coming in 2025. Starting in 2025, Medicare recipients will ...
Robert F. Kennedy Jr., recently nominated by President-elect Donald Trump to lead the Department of Health and Human Services (HHS), has proposed a ban on direct-to-consumer pharmaceutical ...
In this piece, LEON USIGBE examines the persistent challenges undermining the Peoples Democratic Party (PDP), highlighting how its unresolved leadership crisis has eroded its strength as a ...
The ruling All Progressives Congress APC on Monday hit back at the Peoples Democratic Party PDP over the latter’s position on the wave of recent deaths recorded due to stampedes at palliatives ...
Attempts to restrict pharmaceutical advertisements have failed many times over the years, often on First Amendment grounds. By Rebecca Robbins Since the late 1990s, drug companies have spent tens ...
In a statement released on Sunday, PDP National Publicity Secretary, Debo Ologunagba, lamented that the incidents highlight the dire consequences of the All Progressives Congress-led Federal ...
There is no cure for atopic dermatitis (eczema), but there are treatments that can help manage this common inflammatory skin condition. Regardless of the stage of the disease, self-care is important ...
In 2025, more than 850,000 Americans with Medicare will benefit from lower prescription drug costs as part of the Inflation Reduction Act. In a Friday announcement, The U.S. Department of Health ...
Gardaí hope to unlock gangland secrets from digital devices seized as part a long-running operation aimed at “taking down” the country’s biggest drug trafficking organisation. The network ...
Zepbound is the first prescription drug approved specifically to treat the common condition. By Dani Blum The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat ...
James B. Rebitzer does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...